Innovotech Inc. Reports Results For Its Second Quarter And Half-Year Ended 30 June 2025

Executive Summary

• Innovotech Inc. reported strong second-quarter revenues of $984,327, contributing to half-year revenues of $2,142,512.
• The company recorded a net loss of $241,199 for the quarter, primarily driven by a one-time executive severance expense of $213,263.
• Revenues showed year-over-year growth compared to Q2 2024 and the first half of 2024, despite a sequential decline from Q1 2025.
• The company acquired intangible assets from BDS Microbial Services Inc. to expand service offerings and redirect clients to its Keystone Labs division.

Key Details

• Q2 2025 Revenue: $984,327
• Half-Year 2025 Revenue: $2,142,512
• Q2 2025 Net Loss: $241,199
• One-Time Expense: $213,263 attributed to executive severances.
• Sequential Revenue Comparison: Down from Q1 2025 revenue of $1,158,185.
• Year-Over-Year Revenue Comparison: Up from Q2 2024 revenue of $712,563 and half-year 2024 revenue of $712,563.
• Strategic Acquisition: Acquired intangible assets from BDS Microbial Services Inc.
• Operational Update: Existing clients from the acquired assets are being redirected to Innovotech’s Keystone Labs division, which has already contributed meaningfully to revenues.
• Company Profile: Diversified Canadian technology company with operations in laboratory services, biotechnology, and proprietary intellectual property. Subsidiaries include Innovotech Labs Corporation (contract research/antimicrobial testing) and Keystone Labs Inc. (DEL-accredited lab). Owns 60% stake in NouLifeSciences Inc.

Notable Quotes

• “We continue to execute on several linked, sequential projects from clients that have extended across several quarters and will continue to do so. Revenues can be spiky but we are focussed on long-term profitable growth and pleased with the progress to date,” said Craig Milne, CEO.